102 related articles for article (PubMed ID: 24489105)
1. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.
Wilmott JS; Haydu LE; Menzies AM; Lum T; Hyman J; Thompson JF; Hersey P; Kefford RF; Scolyer RA; Long GV
J Immunol; 2014 Mar; 192(5):2505-13. PubMed ID: 24489105
[TBL] [Abstract][Full Text] [Related]
2. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
Wilmott JS; Long GV; Howle JR; Haydu LE; Sharma RN; Thompson JF; Kefford RF; Hersey P; Scolyer RA
Clin Cancer Res; 2012 Mar; 18(5):1386-94. PubMed ID: 22156613
[TBL] [Abstract][Full Text] [Related]
3. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
Hong DS; Vence L; Falchook G; Radvanyi LG; Liu C; Goodman V; Legos JJ; Blackman S; Scarmadio A; Kurzrock R; Lizee G; Hwu P
Clin Cancer Res; 2012 Apr; 18(8):2326-35. PubMed ID: 22355009
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
6. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
7. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
9. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
11. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
[TBL] [Abstract][Full Text] [Related]
12. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
14. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
16. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes.
Peiffer L; Farahpour F; Sriram A; Spassova I; Hoffmann D; Kubat L; Stoitzner P; Gambichler T; Sucker A; Ugurel S; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2021 Jun; 70(6):1635-1647. PubMed ID: 33275172
[TBL] [Abstract][Full Text] [Related]
17. The density and spatial tissue distribution of CD8
Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
[TBL] [Abstract][Full Text] [Related]
18. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
[TBL] [Abstract][Full Text] [Related]
19. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
20. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
